Dysfunction of norepinephrine and its metabolites in Alzheimer's dementia – A review with meta-analysis

Altman, 2000, TN, Statistics with Confidence Azorin, 1990, “Total plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) in alzheimer patients. Comparison with depressives and normal controls,”, Int. J. Geriatr. Psychiatry, vol. 5, 389, 10.1002/gps.930050607 Baker, 1989, “The human locus coeruleus complex: an immunohistochemical and three dimensional reconstruction study, Exp. Brain Res., vol. 77, 257, 10.1007/BF00274983 Bemelmans, 2007, “Plasma cortisol and norepinephrine in Alzheimer’s disease: opposite relations with recall performance and stage of progression,”, Acta Neuropsychiatr., vol. 19, 231, 10.1111/j.1601-5215.2006.00172.x Blennow, 1992, “Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer’s disease,”, Neurobiol. Aging, vol. 13, 107, 10.1016/0197-4580(92)90017-R Bondareff, 1982, “Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia,”, Neurology, vol. 32, 164-164, 10.1212/WNL.32.2.164 Braak, 2011, Tredici, “The pathological process underlying Alzheimer’s disease in individuals under thirty, Acta Neuropathol., vol. 121, 171, 10.1007/s00401-010-0789-4 Braak, 2011, Tredici, “Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years, J. Neuropathol. Exp. Neurol., vol. 70, 960, 10.1097/NEN.0b013e318232a379 Chalermpalanupap, 2018, “Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice,”, J. Neurosci., vol. 38, 74, 10.1523/JNEUROSCI.1483-17.2017 Cooper H, 1994 Eisenhofer, 2004, “Catecholamine metabolism: a contemporary view with implications for physiology and medicine,”, Pharmacol. Rev., vol. 56, 331, 10.1124/pr.56.3.1 Elrod, 1997, “Effects of Alzheimer’s disease severity on cerebrospinal fluid norepinephrine concentration,”, Am. J. Psychiatry, vol. 154, 25, 10.1176/ajp.154.1.25 Engelborghs, 2008, “The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia, Neurochem. Int., vol. 52, 1052, 10.1016/j.neuint.2007.10.018 Feinstein, 2016, “Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system,”, J. Neurochem., vol. 139, 154, 10.1111/jnc.13447 Hammerschmidt, 2013, “Selective Loss of Noradrenaline Exacerbates Early Cognitive Dysfunction and Synaptic Deficits in APP/PS1 Mice,”, Biol. Psychiatry, vol. 73, 454, 10.1016/j.biopsych.2012.06.013 Hartikainen, 1992, “Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis and normal controls,”, J. Neural Transm. - Park. Dis. Dement. Sect., vol. 4, 53, 10.1007/BF02257622 Heneka, 2002, “Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer’s disease, J. Neurosci., vol. 22, 2434, 10.1523/JNEUROSCI.22-07-02434.2002 Heneka, 2010, “Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine,”, Proc. Natl. Acad. Sci., vol. 107, 6058, 10.1073/pnas.0909586107 Higgins, 2019, Choosing effect measures and computing estimates of effect Hoogendijk, 1999, “Increased activity of surviving locus ceruleus neurons in Alzheimer’s disease, Ann. Neurol., vol. 45, 82, 10.1002/1531-8249(199901)45:1<82::AID-ART14>3.0.CO;2-T Iversen, 1983, “Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer’s type, Neurosci. Lett., vol. 39, 95, 10.1016/0304-3940(83)90171-4 Janssens, 2018, “Cerebrospinal fluid and serum MHPG improve Alzheimer’s disease versus dementia with Lewy bodies differential diagnosis,”, Alzheimer’s Dement. Diagn., Assess. Dis. Monit., vol. 10, 172 Janssens, 2019, Deyn, “Sampling issues of cerebrospinal fluid and plasma monoamines: Investigation of the circadian rhythm and rostrocaudal concentration gradient, Neurochem. Int., vol. 128, 154, 10.1016/j.neuint.2019.04.015 Kalinin, 2007, “Noradrenaline deficiency in brain increases β-amyloid plaque burden in an animal model of Alzheimer’s disease,”, Neurobiol. Aging, vol. 28, 1206, 10.1016/j.neurobiolaging.2006.06.003 Kalinin, 2012, “The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer’s disease,”, Neurobiol. Aging, vol. 33, 1651, 10.1016/j.neurobiolaging.2011.04.012 Kawakatsu, 1990, “Acetylcholinesterase activities and monoamine metabolite levels in the cerebrospinal fluid of patients with alzheimer’s disease,”, Biol. Psychiatry, vol. 28, 387, 10.1016/0006-3223(90)90407-S Khakpour-Taleghani, 2009, “Effect of reversible inactivation of locus ceruleus on spatial reference and working memory,”, Neuroscience, vol. 158, 1284, 10.1016/j.neuroscience.2008.11.001 Kummer, 2014, “Ear2 Deletion Causes Early Memory and Learning Deficits in APP/PS1 Mice,”, J. Neurosci., vol. 34, 8845, 10.1523/JNEUROSCI.4027-13.2014 Lapiz, 2001, “Effects of central noradrenaline depletion by the selective neurotoxin DSP-4 on the behaviour of the isolated rat in the elevated plus maze and water maze, Psychopharmacol. (Berl. )., vol. 155, 251, 10.1007/s002130100702 Lourenco, 2021, “Cerebrospinal Fluid Neurotransmitters, Cytokines, and Chemokines in Alzheimer’s and Lewy Body Diseases,”, J. Alzheimer’s Dis., vol. 82, 1067, 10.3233/JAD-210147 Mair, 2005, “Effects of clonidine in the locus coeruleus on prefrontal- and hippocampal-dependent measures of attention and memory in the rat,”, Psychopharmacol. (Berl. )., vol. 181, 280, 10.1007/s00213-005-2263-x Malm, 1991, “CSF monoamine metabolites, cholinesterases and lactate in the adult hydrocephalus syndrome (normal pressure hydrocephalus) related to CSF hydrodynamic parameters, J. Neurol. Neurosurg. Psychiatry, vol. 54, 252, 10.1136/jnnp.54.3.252 Marcyniuk, 1986, “The topography of cell loss from locus caeruleus in Alzheimer’s disease, J. Neurol. Sci., vol. 76, 335, 10.1016/0022-510X(86)90179-6 Marino, 2005, “Genetic reduction of noradrenergic function alters social memory and reduces aggression in mice,”, Behav. Brain Res., vol. 161, 197, 10.1016/j.bbr.2005.02.005 Martignoni, 1992, “Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson’s disease, multiple system atrophy and dementia of the Alzheimer type,”, J. Neural Transm. - Park. Dis. Dement. Sect., vol. 4, 191, 10.1007/BF02260903 Matthews, 2002, “Noradrenergic changes, aggressive behavior, and cognition in patients with dementia, Biol. Psychiatry, vol. 51, 407, 10.1016/S0006-3223(01)01235-5 Molchan, 1991, “CSF monoamine metabolites and somatostatin in Alzheimer’s disease and major depression,”, Biol. Psychiatry, vol. 29, 1110, 10.1016/0006-3223(91)90253-I Murchison, 2004, “A Distinct Role for Norepinephrine in Memory Retrieval,”, Cell, vol. 117, 131, 10.1016/S0092-8674(04)00259-4 Nazarali, 1992, “Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer’s disease: a postmortem study, Cell. Mol. Neurobiol., vol. 12, 581, 10.1007/BF00711237 Page, 2021, “The PRISMA 2020 statement: an updated guideline for reporting systematic reviews,”, BMJ, n71, 10.1136/bmj.n71 Palmer, 1987, “Monoaminergic innervation of the frontal and temporal lobes in Alzheimer’s disease, Brain Res., vol. 401, 231, 10.1016/0006-8993(87)91408-9 Parnetti, 1992, “CSF monoamine metabolites in old age dementias,”, Mol. Chem. Neuropathol., vol. 16, 143, 10.1007/BF03159966 Raskind, 1999, “Patterns of cerebrospinal fluid catechols support increased central noradrenergic responsiveness in aging and Alzheimer’s disease,”, Biol. Psychiatry, vol. 46, 756, 10.1016/S0006-3223(99)00008-6 Rüb, 2016, “The Brainstem Tau Cytoskeletal Pathology of Alzheimer’s Disease: A Brief Historical Overview and Description of its Anatomical Distribution Pattern, Evolutional Features, Pathogenetic and Clinical Relevance, Curr. Alzheimer Res., vol. 13, 1178, 10.2174/1567205013666160606100509 Sheline, 1998, “Higher Cerebrospinal Fluid MHPG in Subjects With Dementia of the Alzheimer Type: Relationship With Cognitive Dysfunction,”, Am. J. Geriatr. Psychiatry, vol. 6, 155 Sjögren, 1998, “Decreased monoamine metabolites in frontotemporal dementia and Alzheimer’s disease,”, Neurobiol. Aging, vol. 19, 379, 10.1016/S0197-4580(98)00086-4 Sontag, 2008, “Effects of the noradrenergic neurotoxin DSP4 on spatial memory in the rat,”, J. Neural Transm., vol. 115, 299, 10.1007/s00702-007-0830-5 Storga, 1996, “Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients, Neurosci. Lett., vol. 203, 29, 10.1016/0304-3940(95)12256-7 Szot, 2006, “Compensatory Changes in the Noradrenergic Nervous System in the Locus Ceruleus and Hippocampus of Postmortem Subjects with Alzheimer’s Disease and Dementia with Lewy Bodies,”, J. Neurosci., vol. 26, 467, 10.1523/JNEUROSCI.4265-05.2006 Team, 2019 Theofilas, 2017, “Locus coeruleus volume and cell population changes during Alzheimer’s disease progression: A stereological study in human postmortem brains with potential implication for early-stage biomarker discovery, Alzheimers Dement., vol. 13, 236, 10.1016/j.jalz.2016.06.2362 Thomas, 1997, “Disruption of the dopamine beta-hydroxylase gene in mice suggests roles for norepinephrine in motor function, learning, and memory, Behav. Neurosci., vol. 111, 579, 10.1037/0735-7044.111.3.579 Tohgi, 1992, “Concentration of monoamines and their metabolites in the cerebrospinal fluid from patients with senile dementia of the Alzheimer type and vascular dementia of the Binswanger type,”, J. Neural Transm. - Park. Dis. Dement. Sect., vol. 4, 69, 10.1007/BF02257623 Umegaki, 2000, “Low plasma epinephrine in elderly female subjects of dementia of Alzheimer type,”, Brain Res., vol. 858, 67, 10.1016/S0006-8993(99)02440-3 van Hooren, 2021, “Elevated norepinephrine metabolism is linked to cortical thickness in the context of Alzheimer’s disease pathology,”, Neurobiol. Aging, vol. 102, 17, 10.1016/j.neurobiolaging.2021.01.024 Vitiello, 1993, “Autonomic dysfunction in patients with dementia of the Alzheimer type,”, Biol. Psychiatry, vol. 34, 428, 10.1016/0006-3223(93)90233-4 Volicer, 1985, “Catecholamine metabolites and cyclic nucleotides in cerebrospinal fluid in dementia of Alzheimer type,”, J. Gerontol., vol. 40, 708, 10.1093/geronj/40.6.708 Ziegler, 1977, “Norepinephrine and 3-methoxy-4-hydroxyphenyl glycol gradients in human cerebrospinal fluid,”, Am. J. Psychiatry, vol. 134, 565, 10.1176/ajp.134.5.565